Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates from Spain and molecular characterisation of borderline susceptible and resistant strains

被引：2
|
作者：
Soler-Gomez, A. [1 ]
Arca-Suarez, J. [2 ]
Gonzalez-Gomez, M. C. [2 ]
Galan-Sanchez, F. [2 ]
Rodriguez-Iglesias, M. [2 ,3 ]
机构：
[1] Puerta Mar Univ Hosp, Dept Internal Med, Cadiz, Spain
[2] Puerta Mar Univ Hosp, Dept Clin Microbiol, Ave Ana Viya 21, Cadiz 11009, Spain
[3] Cadiz Univ, Dept Biomed Biotechnol & Publ Hlth, Cadiz, Spain
来源：
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE | 2018年 / 15卷
关键词：
D O I：
10.1016/j.jgar.2018.10.002
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：171 / 172
页数：2
相关论文
共 50 条
  • [1] In vitro activity of ceftaroline against methicillin-resistant Staphylococcus aureus isolates
    Basireddy, S.
    Singh, M.
    Ali, S.
    Kabra, V.
    INDIAN JOURNAL OF MEDICAL MICROBIOLOGY, 2015, 33 (03) : 464 - +
  • [2] CEFTAROLINE: A NEW CEPHALOSPORIN WITH ACTIVITY AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA)
    Varghese, Anu Anna
    Biju, Roshni Acha
    Renuka, R.
    Abraham, Elessy
    INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 6 (04): : 7022 - 7028
  • [3] Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013–2014 at the Geneva University Hospitals
    D. O. Andrey
    P. François
    C. Manzano
    E. J. Bonetti
    S. Harbarth
    J. Schrenzel
    W. L. Kelley
    A. Renzoni
    European Journal of Clinical Microbiology & Infectious Diseases, 2017, 36 : 343 - 350
  • [4] Antimicrobial activity of ceftaroline against methicillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2013-2014 at the Geneva University Hospitals
    Andrey, D. O.
    Francois, P.
    Manzano, C.
    Bonetti, E. J.
    Harbarth, S.
    Schrenzel, J.
    Kelley, W. L.
    Renzoni, A.
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2017, 36 (02) : 343 - 350
  • [5] In vitro activity of ceftaroline against methicillin-resistant and methicillin-susceptible Staphylococcus aureus clinical isolates from a tertiary hospital in Greece
    Tychala, Areti
    Protonotariou, Efthymia
    Meletis, Georgios
    Tsoha, Anna
    Mantzana, Paraskevi
    Vasilaki, Olga
    Kagkalou, Georgia
    Skoura, Lemonia
    NEW MICROBIOLOGICA, 2021, 44 (02): : 125 - 128
  • [6] Antimicrobial activity of hydralazine against methicillin-resistant and methicillin-susceptible Staphylococcus aureus
    Stefany Aires do Nascimento, Francisca B.
    do Amaral Valente Sa, Livia Gurgel
    de Andrade Neto, Joao B.
    da Silva, Lisandra Juvencio
    Rodrigues, Daniel Sampaio
    de Farias Cabral, Vitoria P.
    Barbosa, Amanda Dias
    Almeida Moreira, Lara E.
    Braga Vasconcelos, Camille R.
    Cavalcanti, Bruno Coelho
    Franca Rios, Maria E.
    Silva, Jacilene
    Marinho, Emmanuel Silva
    dos Santos, Helcio Silva
    de Mesquita, Jaco R. L.
    Pinto Lobo, Marina Duarte
    de Moraes, Manoel Odorico
    Nobre Junior, Helio, V
    da Silva, Cecilia Rocha
    FUTURE MICROBIOLOGY, 2024, 19 (02) : 91 - 106
  • [7] Plant Flavonoids with Antimicrobial Activity against Methicillin-Resistant Staphylococcus aureus (MRSA)
    Xu, Shengnan
    Kang, Ayue
    Tian, Yue
    Li, Xinhui
    Qin, Shangshang
    Yang, Ruige
    Guo, Yong
    ACS INFECTIOUS DISEASES, 2024, 10 (09): : 3086 - 3097
  • [8] Discrimination of methicillin-resistant Staphylococcus aureus from borderline-resistant and susceptible isolates by different methods
    Resende, CA
    Figueiredo, AMS
    JOURNAL OF MEDICAL MICROBIOLOGY, 1997, 46 (02) : 145 - 149
  • [9] Ceftaroline: A Novel Cephalosporin with Activity against Methicillin-resistant Staphylococcus aureus
    Saravolatz, Louis D.
    Stein, Gary E.
    Johnson, Leonard B.
    CLINICAL INFECTIOUS DISEASES, 2011, 52 (09) : 1156 - 1163
  • [10] Ceftaroline Fosamil: A Cephalosporin With Activity Against Methicillin-Resistant Staphylococcus Aureus
    Poon, Henry
    Chang, Mei H.
    Fung, Horatio B.
    CLINICAL THERAPEUTICS, 2012, 34 (04) : 743 - 765
12345